{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:55:17Z","timestamp":1782975317936,"version":"3.54.5"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"DOI":"10.1186\/s12962-025-00665-1","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:51:18Z","timestamp":1761745878000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-effectiveness of RefluxStop compared to proton pump inhibitors and Nissen fundoplication for management of persistent gastroesophageal reflux disease in Norway"],"prefix":"10.1186","volume":"23","author":[{"given":"Sam","family":"Harper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muralikrishnan","family":"Kartha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Mealing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Eftang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Gaupset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"issue":"3","key":"665_CR1","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3109\/13814780903260764a","volume":"15","author":"JP Gisbert","year":"2009","unstructured":"Gisbert JP, et al. Consultation rates and characteristics of gastro-oesophageal reflux disease in primary care: a European observational study. Eur J Gen Pract. 2009;15(3):154\u201360","journal-title":"Eur J Gen Pract"},{"issue":"2","key":"665_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1053\/j.gastro.2017.07.045","volume":"154","author":"JE Richter","year":"2018","unstructured":"Richter JE, Rubenstein JH. Presentation and epidemiology of gastroesophageal reflux disease. Gastroenterology. 2018;154(2):267\u201376","journal-title":"Gastroenterology"},{"key":"665_CR3","doi-asserted-by":"crossref","unstructured":"Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900\u201320. Quiz 1943.","DOI":"10.1111\/j.1572-0241.2006.00630.x"},{"issue":"2","key":"665_CR4","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000080308","volume":"22","author":"I Wiklund","year":"2004","unstructured":"Wiklund I. Review of the quality of life and burden of illness in gastroesophageal reflux disease. Dig Dis. 2004;22(2):108\u201314","journal-title":"Dig Dis"},{"key":"665_CR5","unstructured":"GBD 2017 Gastro-oesophageal Reflux Disease Collaborators. The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990-2017. A systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5(6):561\u201381"},{"issue":"10","key":"665_CR6","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1136\/gutjnl-2011-300715","volume":"61","author":"E Ness-Jensen","year":"2012","unstructured":"Ness-Jensen E, et al. Changes in prevalence, incidence and spontaneous loss of gastro-oesophageal reflux symptoms: a prospective population-based cohort study, the HUNT study. Gut. 2012;61(10):1390\u201397","journal-title":"Gut"},{"issue":"11","key":"665_CR7","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1080\/00365520410003498","volume":"39","author":"M Nilsson","year":"2004","unstructured":"Nilsson M, et al. Prevalence of gastro-oesophageal reflux symptoms and the influence of age and sex. Scand J Gastroenterol. 2004;39(11):1040\u201345","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"665_CR8","doi-asserted-by":"publisher","first-page":"Itc1","DOI":"10.7326\/AITC201507070","volume":"163","author":"IG Harnik","year":"2015","unstructured":"Harnik IG. In the clinic. Gastroesophageal reflux disease. Ann Intern Med. 2015;163(1):Itc1","journal-title":"Ann Intern Med"},{"issue":"1","key":"665_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.14309\/ajg.0000000000001538","volume":"117","author":"PO Katz","year":"2022","unstructured":"Katz PO, et al. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022;117(1):27\u201356","journal-title":"Am J Gastroenterol"},{"key":"665_CR10","doi-asserted-by":"publisher","first-page":"h 3169","DOI":"10.1136\/bmj.h3169","volume":"350","author":"J Maret-Ouda","year":"2015","unstructured":"Maret-Ouda J, Brusselaers N, Lagergren J. What is the most effective treatment for severe gastro-oesophageal reflux disease? BMJ. 2015;350:h 3169","journal-title":"BMJ"},{"issue":"6","key":"665_CR11","doi-asserted-by":"publisher","first-page":"e016505","DOI":"10.1136\/bmjopen-2017-016505","volume":"7","author":"J Maret-Ouda","year":"2017","unstructured":"Maret-Ouda J, et al. Cohort profile: the nordic antireflux surgery cohort (NordAsco). BMJ Open. 2017;7(6):e016505","journal-title":"BMJ Open"},{"issue":"1","key":"665_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4045\/tidsskr.12.0019","volume":"133","author":"JG Hatlebakk","year":"2013","unstructured":"Hatlebakk JG, et al. Correct use of proton pump inhibitors for gastro-oesophageal reflux disease. Tidsskr Nor Laegeforen. 2013;133(1):43\u201346","journal-title":"Tidsskr Nor Laegeforen"},{"issue":"15","key":"665_CR13","first-page":"1990","volume":"125","author":"E Trondsen","year":"2005","unstructured":"Trondsen E, Bakken IJ, Skjeldestad FE. Anti-reflux surgery in Norway. Tidsskr Nor Laegeforen. 2005;125(15):1990\u201392","journal-title":"Tidsskr Nor Laegeforen"},{"key":"665_CR14","doi-asserted-by":"crossref","unstructured":"Bjelovi\u0107 M, et al. Non-active implantable device treating acid reflux with a new dynamic treatment approach: 1-year results: RefluxStop\u2122 device; a new method in acid reflux surgery obtaining CE mark. BMC Surg. 2020;20(1):159","DOI":"10.1186\/s12893-020-00794-9"},{"issue":"6","key":"665_CR15","doi-asserted-by":"publisher","first-page":"2101333","DOI":"10.1080\/21645515.2022.2101333","volume":"18","author":"LS Nymark","year":"2022","unstructured":"Nymark LS, et al. Cost-utility analysis of the universal pneumococcal vaccination programme for older adults in Norway. Hum Vaccin Immunother. 2022;18(6):2101333","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"665_CR16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1080\/13696998.2023.2201063","volume":"26","author":"S Harper","year":"2023","unstructured":"Harper S, et al. Cost-effectiveness of a novel, non-active implantable device as a treatment for refractory gastro-esophageal reflux disease. J Med Econ. 2023;26(1):603\u201313","journal-title":"J Med Econ"},{"key":"665_CR17","unstructured":"National Institute for Health and Care Excellence, in Clinical guideline [CG184]: gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management. NICE: National Institute for Health and Care Excellence: London;2019"},{"key":"665_CR18","unstructured":"Briggs A, et al. Decision modelling for health economic evaluation. 2025. https:\/\/global.oup.com\/academic\/product\/decision-modelling-for-health-economic-evaluation-9780198526629?cc=gb%26lang=en%26."},{"key":"665_CR19","doi-asserted-by":"crossref","unstructured":"Grant A, et al. The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease - a UK collaborative study. The REFLUX Trial. Health Technol Assess. 2008;12(31):1\u2013181, iii-iv","DOI":"10.3310\/hta12310"},{"key":"665_CR20","doi-asserted-by":"crossref","unstructured":"Spechler SJ, et al. Randomized trial of medical versus surgical treatment for refractory heartburn. N Engl J Med. 2019;381(16):1513\u201323","DOI":"10.1056\/NEJMoa1811424"},{"key":"665_CR21","doi-asserted-by":"crossref","unstructured":"Bojke L, Hornby E, Sculpher M. A comparison of the cost effectiveness of pharmacotherapy or surgery (laparoscopic fundoplication) in the treatment of GORD. Pharmacoeconomics. 2007;25(10):829\u201341","DOI":"10.2165\/00019053-200725100-00003"},{"key":"665_CR22","doi-asserted-by":"crossref","unstructured":"Zehetner J, et al. Looking back on a gold standard: a systematic literature review of laparoscopic nissen fundoplication as an anti-reflux treatment option. Eur Surg. 2024;56:143\u201371.","DOI":"10.1007\/s10353-024-00836-z"},{"key":"665_CR23","doi-asserted-by":"crossref","unstructured":"Hars\u00e1nyi L, Kincses Z, Altorjay \u00c1. Acid reflux management with the RefluxStop implant: a prospective multicenter trial with 3-year outcomes. Digestive Dis Sci. 2025;70(2):665\u201374.","DOI":"10.1007\/s10620-024-08788-w"},{"key":"665_CR24","unstructured":"National Institute for Health and Care Excellence (NICE). Dyspepsia and gastro-oesophageal reflux disease. Appendix H: Full Health Economics Report. 2014 Available from: https:\/\/www.nice.org.uk\/guidance\/cg184\/evidence\/appendix-h-full-health-economics-report-pdf-6955335252"},{"key":"665_CR25","unstructured":"WHO CVD Risk Chart Working Group. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health. 2019;7(10):e1332\u2013e1345"},{"key":"665_CR26","doi-asserted-by":"crossref","unstructured":"Shiraev TP, Bullen A. Proton pump inhibitors and cardiovascular events: a systematic review. Heart Lung Circ. 2018;27(4):443\u201350","DOI":"10.1016\/j.hlc.2017.10.020"},{"key":"665_CR27","doi-asserted-by":"crossref","unstructured":"Collins G, Altman D. Predicting the risk of chronic kidney disease in the UK: an evaluation of QKidney\u00ae scores using a primary care database. Br J Gen Pract. 2012;62(597):e243\u201350","DOI":"10.3399\/bjgp12X636065"},{"issue":"1","key":"665_CR28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cegh.2017.12.008","volume":"7","author":"SS Hussain","year":"2019","unstructured":"Hussain SS, Habib A, Najmi Ak A. Proton pump inhibitors use and risk of chronic kidney disease: evidence-based meta-analysis of observational studies. Clin Epidemiol And Global Health. 2019;7(1):46\u201352","journal-title":"Clin Epidemiol And Global Health"},{"issue":"4","key":"665_CR29","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385\u201397","journal-title":"Osteoporos Int"},{"issue":"1","key":"665_CR30","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00198-015-3365-x","volume":"27","author":"B Zhou","year":"2016","unstructured":"Zhou B, et al. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int. 2016;27(1):339\u201347","journal-title":"Osteoporos Int"},{"key":"665_CR31","first-page":"e263","volume-title":"Pneumonia incidence trends in UK primary care from 2002 to 2017: population-based cohort study","author":"X Sun","year":"2019","unstructured":"Sun X, Douiri A, Gulliford M. Pneumonia incidence trends in UK primary care from 2002 to 2017: population-based cohort study. Epidemiol Infect. 2019;147:e263"},{"issue":"6","key":"665_CR32","doi-asserted-by":"publisher","first-page":"e0128004","DOI":"10.1371\/journal.pone.0128004","volume":"10","author":"AA Lambert","year":"2015","unstructured":"Lambert AA, et al. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015;10(6):e0128004","journal-title":"PLoS One"},{"key":"665_CR33","unstructured":"Public Health England. Clostridium difficile infection: mandatory surveillance 2017\/18. 2018 2023 5]; Available from: May. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/724368\/CDI_summary_2018.pdf."},{"issue":"7","key":"665_CR34","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/ajg.2012.179","volume":"107","author":"S Janarthanan","year":"2012","unstructured":"Janarthanan S, et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107(7):1001\u201310","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"665_CR35","doi-asserted-by":"publisher","first-page":"e017739","DOI":"10.1136\/bmjopen-2017-017739","volume":"7","author":"N Brusselaers","year":"2017","unstructured":"Brusselaers N, et al. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 2017;7(10):e017739","journal-title":"BMJ Open"},{"issue":"8","key":"665_CR36","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1007\/s00464-016-5370-3","volume":"31","author":"D Skubleny","year":"2017","unstructured":"Skubleny D, et al. LINX(\u00ae) magnetic esophageal sphincter augmentation versus Nissen fundoplication for gastroesophageal reflux disease: a systematic review and meta-analysis. Surg Endosc. 2017;31(8):3078\u201384","journal-title":"Surg Endosc"},{"key":"665_CR37","doi-asserted-by":"crossref","unstructured":"Szende A, et al. Self-reported population health: an international perspective based on EQ-5D. Dordrecht (NL): Springer; 2014.","DOI":"10.1007\/978-94-007-7596-1"},{"issue":"5","key":"665_CR38","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s00464-002-8568-5","volume":"17","author":"WG Ainslie","year":"2003","unstructured":"Ainslie WG, et al. Micropuncture cholecystectomy vs conventional laparoscopic cholecystectomy: a randomized controlled trial. Surg Endosc. 2003;17(5):766\u201372","journal-title":"Surg Endosc"},{"issue":"5","key":"665_CR39","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/clpt.2013.13","volume":"93","author":"JC Bouvy","year":"2013","unstructured":"Bouvy JC, et al. The cost-effectiveness of periodic safety update reports for biologicals in Europe. Clin Pharmacol Ther. 2013;93(5):433\u201342","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"665_CR40","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/03007995.2018.1552407","volume":"35","author":"V Pollit","year":"2019","unstructured":"Pollit V, et al. A cost-effectiveness analysis of endoscopic eradication therapy for management of dysplasia arising in patients with Barrett\u2019s oesophagus in the United Kingdom. Curr Med Res Opin. 2019;35(5):805\u201315","journal-title":"Curr Med Res Opin"},{"issue":"35","key":"665_CR41","doi-asserted-by":"publisher","first-page":"6500","DOI":"10.3748\/wjg.v23.i35.6500","volume":"23","author":"A Trifan","year":"2017","unstructured":"Trifan A, et al. Proton pump inhibitors therapy and risk of Clostridium difficile infection: systematic review and meta-analysis. World J Gastroenterol. 2017;23(35):6500\u201315","journal-title":"World J Gastroenterol"},{"issue":"5","key":"665_CR42","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/intqhc\/mzaa041","volume":"32","author":"PA Nguyen","year":"2020","unstructured":"Nguyen PA, et al. Meta-analysis of proton pump inhibitors induced risk of community-acquired pneumonia. Int J Qual Health Care. 2020;32(5):292\u201399","journal-title":"Int J Qual Health Care"},{"issue":"3","key":"665_CR43","doi-asserted-by":"publisher","first-page":"141","DOI":"10.11005\/jbm.2018.25.3.141","volume":"25","author":"Y Nassar","year":"2018","unstructured":"Nassar Y, Richter S. Proton-pump inhibitor use and fracture risk: An updated systematic review and meta-analysis. J Bone Metab. 2018;25(3):141\u201351","journal-title":"J Bone Metab"},{"key":"665_CR44","doi-asserted-by":"crossref","unstructured":"Poly TN, et al. Proton pump inhibitor use and risk of gastric cancer: current evidence from epidemiological studies and critical appraisal. Cancers (Basel). 2022;14(13):3052","DOI":"10.3390\/cancers14133052"},{"key":"665_CR45","doi-asserted-by":"crossref","unstructured":"Nochaiwong S, et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol Dial Transpl. 2018;33(2):331\u201342","DOI":"10.1093\/ndt\/gfw470"},{"issue":"8","key":"665_CR46","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/apt.14955","volume":"48","author":"R Batchelor","year":"2018","unstructured":"Batchelor R, et al. Systematic review with meta-analysis: risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel. Aliment Pharmacol Ther. 2018;48(8):780\u201396","journal-title":"Aliment Pharmacol Ther"},{"issue":"15","key":"665_CR47","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1001\/jama.287.15.1972","volume":"287","author":"N Shaheen","year":"2002","unstructured":"Shaheen N, Ransohoff DF. Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review. JAMA. 2002;287(15):1972\u201381","journal-title":"JAMA"},{"key":"665_CR48","doi-asserted-by":"crossref","unstructured":"Yousef F, et al. The incidence of esophageal cancer and high-grade dysplasia in Barrett\u2019s esophagus: a systematic review and meta-analysis. Am J Epidemiol. 2008;168(3):237\u201349","DOI":"10.1093\/aje\/kwn121"},{"key":"665_CR49","unstructured":"Norwegian DRG. 2023]; Available from: August 7. https:\/\/www.helsedirektoratet.no\/tema\/finansiering\/innsatsstyrt-finansiering-og-drg-systemet\/innsatsstyrt-finansiering-isf#regelverk."},{"key":"665_CR50","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1332\/174426410X482999","volume":"6","author":"I Shemilt","year":"2010","unstructured":"Shemilt I, Thomas J, Morciano M. A web-based tool for adjusting costs to a specific target currency and price year. Evidence Policy A J Res Debate And Pract. 2010;6(1):51\u201360","journal-title":"Evidence Policy A J Res Debate And Pract"},{"key":"665_CR51","unstructured":"Norwegian Medicines Agency Medicine Database. Norway [internet]. 2023]; Available from: August 7. https:\/\/www.legemiddelsok.no\/"},{"key":"665_CR52","doi-asserted-by":"crossref","unstructured":"Augestad KM, et al. Cost-effectiveness and quality of life in surgeon versus general practitioner-organised colon cancer surveillance: a randomised controlled trial. BMJ Open. 2013;3(4):e002391.","DOI":"10.1136\/bmjopen-2012-002391"},{"issue":"7","key":"665_CR53","doi-asserted-by":"publisher","first-page":"3208","DOI":"10.1007\/s00464-018-6038-y","volume":"32","author":"TR Palser","year":"2018","unstructured":"Palser TR, et al. Variation in laparoscopic anti-reflux surgery across England: a 5-year review. Surg Endosc. 2018;32(7):3208\u201314","journal-title":"Surg Endosc"},{"key":"665_CR54","unstructured":"Pike EH, Ringerike V, Wisl\u00f8ff., Desser T, Harboe A, Klemp I, M. Health technology assessment of the different dialysis modalities in Norway. Report from Kunnskapssenteret no. 19-2013. Oslo: Norwegian Knowledge Centre for the Health Services; 2013"},{"issue":"26","key":"665_CR55","doi-asserted-by":"publisher","first-page":"e26523","DOI":"10.1097\/MD.0000000000026523","volume":"100","author":"C Bugge","year":"2021","unstructured":"Bugge C, et al. Phase- and gender-specific, lifetime, and future costs of cancer: a retrospective population-based registry study. Med (baltim). 2021;100(26):e26523","journal-title":"Med (baltim)"},{"key":"665_CR56","doi-asserted-by":"crossref","unstructured":"Kerr M, et al. Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrol Dial Transplant. 2012;27 Suppl 3(Suppl 3):iii73\u201380","DOI":"10.1093\/ndt\/gfs269"},{"key":"665_CR57","doi-asserted-by":"crossref","unstructured":"Eriksson D, et al. Real-world costs of autosomal dominant polycystic kidney disease in the nordics. BMC Health Serv Res. 2017;17(1):560","DOI":"10.1186\/s12913-017-2513-8"},{"issue":"1","key":"665_CR58","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12882-022-02903-7","volume":"23","author":"K Kim","year":"2022","unstructured":"Kim K, et al. Cost effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in patients with CKD in Norway and Sweden. BMC Nephrol. 2022;23(1):281","journal-title":"BMC Nephrol"},{"key":"665_CR59","unstructured":"Kidneyfailurerisk.com. The kidney failure risk equation. Available from https:\/\/kidneyfailurerisk.com\/. Accessed 7 Oct 2025"},{"key":"665_CR60","doi-asserted-by":"crossref","unstructured":"Akehurst R, et al. The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands. J Med Econ. 2011;14(1):53\u201364","DOI":"10.3111\/13696998.2010.545563"},{"key":"665_CR61","unstructured":"National Institute for Health and Care Excellence. Quality standard [QS110]: pneumonia in adults; 2016. Available from: https:\/\/www.nice.org.uk\/guidance\/qs110"},{"key":"665_CR62","doi-asserted-by":"crossref","unstructured":"Nordling S, et al. The burden of Clostridium Difficile (CDI) infection in hospitals, in Denmark, Finland, Norway and Sweden. Value Health. 2014;17(7):A670","DOI":"10.1016\/j.jval.2014.08.2480"},{"key":"665_CR63","unstructured":"National Institute for Health and Care Excellence (NICE). Technology appraisal guidance [TA378]: Remucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy. 2016. Available from: https:\/\/www.nice.org.uk\/guidance\/ta378. Accessed 7 Oct 2025"},{"key":"665_CR64","doi-asserted-by":"crossref","unstructured":"Laudicella M, et al. Impact of laparoscopic versus open surgery on hospital costs for colon cancer: a population-based retrospective cohort study. BMJ Open. 2016;6(11):e012977","DOI":"10.1136\/bmjopen-2016-012977"},{"key":"665_CR65","unstructured":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations. https:\/\/www.equator-network.org\/reporting-guidelines\/cheers\/"},{"key":"665_CR66","unstructured":"Norwegian Ministry of Health and Care Services. Principles for priority setting in health care - summary of a white paper on priority setting in the Norwegian health care sector [internet]. 2016, Available from: https:\/\/www.regjeringen.no\/contentassets\/439a42e01914a18b21f351143ccc6af\/en-gb\/pdfs\/stm201520160034000engpdfs.pdf.43. Oslo (Norway): Norwegian Government"},{"key":"665_CR67","doi-asserted-by":"crossref","unstructured":"Hars\u00e1nyi L, et al. Food passageway-related sequelae in the RefluxStop prospective multicenter trial: Patient-centric outcomes of dysphagia, odynophagia, gas-bloating, and inability to belch and\/or vomit at 5 years. Surg Endosc. 2025;39(7):4615\u201327.","DOI":"10.1007\/s00464-025-11818-x"},{"key":"665_CR68","doi-asserted-by":"crossref","unstructured":"Hars\u00e1nyi L, et al. Five-year clinical outcomes of RefluxStop surgery in the treatment of acid reflux: a prospective multicenter trial of safety and effectiveness. Surg Endosc. 2025;39(9):6163\u201379.","DOI":"10.1007\/s00464-025-11979-9"},{"key":"665_CR69","doi-asserted-by":"publisher","unstructured":"Schoppmann S, et al. Safety outcomes in 602 GERD patients that underwent the RefluxStop procedure: a multi-center real-world observational study from 22 independent centers across six European countries with a mean follow-up of 2 years. Abstract ID: 128. Presented at the American Foregut Society (AFS) 2025. Foregut. 2025;0(0):2025. https:\/\/doi.org\/10.1177\/26345161251371922","DOI":"10.1177\/26345161251371922"},{"key":"665_CR70","doi-asserted-by":"crossref","unstructured":"Zhang D, et al. Global, regional and national burden of gastroesophageal reflux disease, 1990-2019. update from the GBD, 2019 study. Ann Med. 2022;54(1):1372\u201384","DOI":"10.1080\/07853890.2022.2074535"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00665-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-025-00665-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00665-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T01:03:09Z","timestamp":1761786189000},"score":1,"resource":{"primary":{"URL":"https:\/\/resource-allocation.biomedcentral.com\/articles\/10.1186\/s12962-025-00665-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["665"],"URL":"https:\/\/doi.org\/10.1186\/s12962-025-00665-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4643281\/v1","asserted-by":"object"}]},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"26 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval and consent for participation were not required for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent for participation"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}